 fibrinolytic potential gliclazide types II diabetic patients study effect gliclazide tissue-type plasminogen activator t-PA fibrinolysis Type diabetic patients residual beta-cell function Type II diabetic patients tolbutamide Type diabetic patients period months Type II diabetic patients tolbutamide Type diabetic patients months treatment gliclazide significant increase plasma concentrations total t-PA antigen stable discontinuation drug plasma concentrations plasminogen activator inhibitor PAI study Next possibility gliclazide t-PA-related fibrinolysis subset Type II diabetics detectable concentrations t-PA treatment tolbutamide concentrations active t-PA months change treatment active t-PA patient undetectable levels months gliclazide plasma concentrations total t-PA antigen group diabetic patients PAI unchanged changes t-PA-related fibrinolysis Type Type II diabetics changes metabolic state blood glucose cholesterol triglycerides gliclazide potential extrametabolic non-insulin-mediated effects t-PA-related fibrinolysis diabetic patients